Concordance Between 2 Means of Temperature Measure in Neutropenic Patients Hospitalized in Intensive Hematology Care Units

Inclusion Criteria: * Major patient admitted to USIH for an aplasia episode of at least 7 days secondary to: * autograft conditioned by melphalan (MLP) or BEAM (BICNU, Etoposide, Aracytine, Melphalan) chemotherapy * Aracytin chemotherapy High dose (HD) or intermediate dose (DI) * Signed informed consent; * Affiliated or beneficiary of a social protection scheme. Exclusion Criteria: * Diarrhea (\> 3 stools /day) at the time of inclusion * Occlusive syndrome at the time of inclusion or patient at risk of developing occlusive syndrome * Persons with or likely to have intestinal disorders that may lead to obstruction of the digestive tract, including diverticulitis * People with digestive tract motility disorders * Persons equipped with a pacemaker or an electro-medical implant * Weight \< 40 kg or BMI \> 30 * Patient for whom an MRI examination may be indicated during the trial period * Patient with proven swallowing disorders * Refusal to participate in the study * Induction of acute leukaemia or allograft * Person under guardianship or curatorship, or deprived of liberty by a judicial or administrative decision * Pregnant, parturient or breastfeeding women; * Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problem, etc.) * Patient who has already been included in the TEMPET trial during treatment